

Combining multiple studies to derive toxicity values: **Path forward as envisioned by the NRC**

IRIS Workshop on the NRC Recommendations

2014.10.16

Yiliang Zhu (yzhu@health.usf.edu)

College of Public Health University of South Florida

NRC Formaldehyde Committee (2011) Recommendation

Integrate information across multiple studies to derive toxicity values (reference values & unit risks)

- A single study is unlikely to trump all others
- Multiple studies and multiple endpoints afford more robust and sufficient dose-response information
- As a result , toxicity values are more reliability, and support evaluation of uncertainty and variability

NRC IRIS Committee (2014)

- EPA made substantial efforts to change and improve the IRIS process following the “road map” suggested by the NRC Formaldehyde Committee (2011)
- The NRC IRIS committee was charged to reviewed the progress made to IRIS process and to provide additional recommendations
- The report contains discussions and illustrations of relevant technical approaches to integrating multiple studies in deriving toxicity values

Combining Information
(at varying level of data
aggregation)

**A Chosen Health
Effect**

Study A – endpoint 1
Study A – endpoint 2
Study B – endpoint 1
Study C – endpoint 3
....
Study K – endpoint 1
Study K – endpoint 4

Pooling data

Pooling dose-
response
models

Pooling toxicity
values

Integrating
across systems

I. Meta-analytic approaches
require compatibility w.r.t.

- Species, exposure duration, exposure route, endpoints, etc.
- Data pooling: compatibility in data elements
- Model pooling: model shape (underlying mechanism) & form
- Toxicity value pooling: parameter/estimate


II. Weights to adjust for

- Study heterogeneity
- Quality

III. System integration requires a
biological or mathematical
mechanism to connect the
multiple systems (studies)

Toxicity values with a range (bounds)

System Integration: A Simple Bayes Model Frame to Integrating Multiple Studies (Fig 7-3)



$$\beta_{\text{animal}} / \beta_{\text{htp}} = U_1$$

$$\beta_{\text{human}} / \beta_{\text{animal}} = U_2$$

β can be any appropriate
dose-response parameter
such as BMD

Table 7-3: An Example

Data systems	Param. BMD ₁₀	BMDL (95%)	Uncertain. Ratio U	Human-equiv. RfD	Prior (log) for human
High-throughput data only	0.1	0.07	U ₁ =1000	0.000007	Log BMD ₁₀ +logU ₁ +logU ₂ ~ N(-2.30,3.71 ²)
Animal assays only	0.85	0.15	U ₂ =10	0.015	
Bayes Integration HTP + animal	0.85	0.048		0.048	log BMD _{animal} +logU ₂ ~ N(-1.65, 1.46 ²)
Human studies only	0.05	0.019		0.019	
Byes Integration HTP + animal + Human	0.066	0.026		0.026	

Bayes Priors and Posteriors in the Example

Data systems	Statistics	Prior distribution (for human)	Posterior distribution (for human)
High-throughput data only	BMD=0.1; BMDL=0.07; U=1000	$\log \text{BMD}_{\text{htp}} + \log U_1 + \log U_2$ $\sim N(-2.30, 3.71^2)$	-
HTP+animal	$\text{Log}(\text{BMD}) = -0.161$; SD=0.9	$\log \text{BMD}_{\text{animal}} + \log U_2$ $\sim N(-1.65, 1.46^2)$	$\log \text{BMD}_{\text{animal}}$ is the posterior based on the prior $\log \text{BMD}_{\text{htp}} + \log U_1$
HTP + animal + Human studies	$\text{Log}(\text{BMD}) = -3.0$; SD=0.5		$\log \text{BMD}_{\text{human}}$ $\sim N(-2.72, 0.224)$

The NRC Envisions

- Existing methods in principle can be adapted to integrate multiple studies systematically
- New methods are needed in the toolbox
- Applications require case-by-case adaptation
- Experience-based guidance needed for appropriate methods
- A critical role EPA plays in this effort